Form 4: Lam Research Director Acquires Shares Under 10b5-1 Plan
Insider Transaction Report
Lam Research Corp. Director Mark Fields acquired 1,635 shares of common stock on November 7, 2025, under a pre-arranged 10b5-1 plan.
Summary
- Director Mark Fields of Lam Research Corp. (LRCX) acquired 1,635 shares of common stock.
- The acquisition occurred on November 7, 2025, with a transaction price of $0 per share, indicating a likely equity grant or vesting.
- Concurrently, 560 shares of common stock were disposed of on the same date, typically for tax withholding purposes related to the acquisition.
- These transactions were executed pursuant to a Rule 10b5-1(c) plan, signifying a pre-arranged purchase or sale schedule.
- Following these reported transactions, Mark Fields beneficially owns 5,322 shares directly and 560 shares indirectly through a Trust.
- The direct beneficial ownership amount of 5,322 shares includes those subject to unvested restricted stock units.
Sentiment
Score: 6
Explanation: The net increase in a director's beneficial ownership, even if from a compensation grant, is generally a positive signal of aligned interests. The 10b5-1 plan adds transparency, contributing to a slightly positive sentiment.
Positives
- Director Mark Fields increased his direct beneficial ownership by a net of 1,075 shares (1,635 acquired minus 560 disposed), which can be interpreted as a positive alignment of interests with shareholders.
- The transactions were conducted under a Rule 10b5-1(c) plan, demonstrating transparency and pre-planning for insider trading activities.
Negatives
- The disposition of 560 shares, while likely for tax withholding, reduces the director's immediate direct holdings.
Future Outlook
The filing does not provide specific forward-looking statements or guidance. However, the director's acquisition of shares, even if part of a compensation plan, may be viewed as a subtle signal of confidence in the company's future prospects.
Industry Context
Insider transactions, such as those reported in this Form 4, are common in the semiconductor equipment industry. While not directly indicative of broader industry trends, they can reflect individual management's perspective on their company's position within the cyclical and technology-driven sector.
Related Party Transactions
- Director Mark Fields' acquisition and disposition of Lam Research Corp. common stock constitutes a related party transaction.
Stakeholder Impact
- Shareholders: The director's increased stake may be perceived as a positive sign of confidence in the company's future, potentially influencing investor sentiment.
- Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 11/07/2025 | Date of earliest transaction for the acquisition and disposition of common stock. |
| 11/10/2025 | Signature date of the reporting person via Power of Attorney. |
Recommendation
holdThis Form 4 details a routine insider transaction involving the acquisition of shares (likely a compensation grant) and a smaller disposition (likely for tax withholding) under a pre-arranged 10b5-1 plan. While the net increase in the director's holdings is a positive for alignment, it does not represent a discretionary open-market purchase that would typically signal a strong conviction. Therefore, this filing alone does not provide sufficient new information to alter an existing investment thesis, warranting a 'hold' recommendation.
Keywords
Lam Research, LRCX, Form 4, Insider Trading, Stock Acquisition, Director, Mark Fields, 10b5-1 Plan, Common Stock, Semiconductor Equipment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.